Epididymo-orchitis following intravesical bacillus Calmette-Guerin therapy
OBJECTIVE: To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette–Guérin (BCG) and to review the incidence of this adverse effect. DATA SOURCES: Information about the patient was obtained from the medical chart. A MEDLINE search of Engl...
Gespeichert in:
Veröffentlicht in: | The Annals of pharmacotherapy 2000-04, Vol.34 (4), p.479-482 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | OBJECTIVE:
To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette–Guérin (BCG) and to review the incidence of this adverse effect.
DATA SOURCES:
Information about the patient was obtained from the medical chart. A MEDLINE search of English-language literature (from January 1976 to April 1999) was conducted.
STUDY SELECTION:
All case reports of BCG-related epididymo-orchitis were evaluated. Review articles describing complications of BCG therapy for bladder cancer and the prevention and treatment of these complications were reviewed.
DATA EXTRACTION:
Studies were evaluated for reports of BCG-related epididymo-orchitis and its treatment.
DATA SYNTHESIS:
Our case report is compared with others reported in the literature. The incidence of BCG-associated epididymo-orchitis is rare.
CONCLUSIONS:
Epididymo-orchitis should be considered as a late complication of BCG therapy for bladder cancer. Proper patient selection may help decrease the risk of complications from BCG therapy. |
---|---|
ISSN: | 1060-0280 1542-6270 |
DOI: | 10.1345/aph.19212 |